Rafferty Asset Management, LLC Inhibrx, Inc. Transaction History

Rafferty Asset Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$32.76 - $39.56 $3.23 Million - $3.9 Million	98,702 Added 95.6%	201,948 $7.06 Million
Q4 2023 Feb 13, 2024	SELL	$14.5 - $38.0 $182,439 - $478,116	-12,582 Reduced 10.86%	103,246 $3.92 Million
Q3 2023 Nov 13, 2023	SELL	$15.75 - $26.31 $259,182 - $432,957	-16,456 Reduced 12.44%	115,828 $2.13 Million
Q2 2023 Aug 11, 2023	SELL	$16.96 - $27.82 $385,653 - $632,598	-22,739 Reduced 14.67%	132,284 $3.43 Million
Q1 2023 May 11, 2023	SELL	$18.45 - $27.14 $770,638 - $1.13 Million	-41,769 Reduced 21.22%	155,023 $2.93 Million
Q4 2022 Feb 13, 2023	BUY	$20.18 - $33.33 $1.29 Million - $2.13 Million	63,793 Added 47.97%	196,792 $4.85 Million
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $1.54 Million - $3.29 Million	132,999 New	132,999 $2.39 Million
Q2 2022 Aug 12, 2022	SELL	$8.52 - $25.26 $809,689 - $2.4 Million	-95,034 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$19.89 - $43.18 $1.12 Million - $2.42 Million	56,121 Added 144.22%	95,034 $2.12 Million
Q4 2021 Feb 10, 2022	BUY	$26.75 - $46.02 $1.04 Million - $1.79 Million	38,913 New	38,913 $1.7 Million

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.